{"id":684741,"date":"2022-09-13T09:34:31","date_gmt":"2022-09-13T13:34:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/"},"modified":"2022-09-13T09:34:31","modified_gmt":"2022-09-13T13:34:31","slug":"shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/","title":{"rendered":"SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n SAN FRANCISCO<\/span>
\n <\/span>, Sept. 13, 2022<\/span><\/span> \/PRNewswire\/ — Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) relating to possible false and misleading statements to investors about its Alzheimer’s drug Aduhelm and an alleged illegal kickback scheme.\u00a0<\/p>\n

Biogen and three of its executive officers are currently subject to a class action securities lawsuit in the U.S. District Court for the District of Massachusetts<\/span> in which plaintiffs allege certain false and misleading statements concerning the commercial prospects for the company’s Alzheimer’s drug, Aduhelm. Specifically, following the FDA’s controversial approval of the drug on June 7, 2021<\/span>, the company and its officers are alleged to have misled investors by, among other things, falsely touting the number of sites available to administer the drug in the U.S. and the extent of coverage to be provided under Medicare, the Veterans Health Administration, and private, third-party insurers. Biogen is also subject to multiple Congressional and regulatory investigations related to the approval and marketing of Aduhelm, including by the SEC, the FTC, the U.S. Department of Health and Human Services, and two committees of the U.S. House of Representatives.<\/p>\n

Separately, Biogen is also being sued by Humana Inc. for what the insurer says were “millions of dollars” in overpayments stemming from an illegal kickback scheme the company allegedly used to market its drugs for the treatment of multiple sclerosis. On December 17, 2020<\/span>, Biogen resolved similar claims with the U.S. Department of Justice for $22 million<\/span>.<\/p>\n

The Schubert Firm is investigating potential breaches of fiduciary duty by Biogen’s officers and directors in connection with these allegations.<\/p>\n

\n If you own stock in Biogen and wish to obtain additional information about your legal
rights, please <\/b>
\n
\n contact us<\/a>
\n <\/b>
\n \u00a0today or visit our website at <\/b>
\n
\n
\n https:\/\/www.classactionlawyers.com\/biogen<\/a>
\n <\/b>
\n .<\/b>\n <\/p>\n

\n About Schubert Jonckheer & Kolbe LLP
<\/b>
\n Schubert Jonckheer & Kolbe<\/a>\u00a0represents shareholders, employees, and consumers in class actions against corporate defendants, as well as shareholders in derivative actions against their officers and directors. The firm is based in San Francisco<\/span>, and with the help of co-counsel, litigates cases nationwide.<\/p>\n

\n Contact
<\/b>
\n Amber L. Schubert<\/span>
\n
Schubert Jonckheer & Kolbe LLP
aschubert@sjk.law<\/a>
Tel: 415-299-8257<\/p>\n

\n \"Cision\" View original content:https:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm-301623151.html<\/a><\/p>\n

SOURCE Schubert Jonckheer & Kolbe LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN FRANCISCO , Sept. 13, 2022 \/PRNewswire\/ — Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) relating to possible false and misleading statements to investors about its Alzheimer’s drug Aduhelm and an alleged illegal kickback scheme.\u00a0 Biogen and three of its executive officers are currently subject to a class action securities lawsuit in the U.S. District Court for the District of Massachusetts in which plaintiffs allege certain false and misleading statements concerning the commercial prospects for the company’s Alzheimer’s drug, Aduhelm. Specifically, following the FDA’s controversial approval of the drug on June 7, 2021, the company and its officers are alleged to have misled investors by, among … <\/p>\n

Continue reading “SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-684741","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN FRANCISCO , Sept. 13, 2022 \/PRNewswire\/ — Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) relating to possible false and misleading statements to investors about its Alzheimer’s drug Aduhelm and an alleged illegal kickback scheme.\u00a0 Biogen and three of its executive officers are currently subject to a class action securities lawsuit in the U.S. District Court for the District of Massachusetts in which plaintiffs allege certain false and misleading statements concerning the commercial prospects for the company’s Alzheimer’s drug, Aduhelm. Specifically, following the FDA’s controversial approval of the drug on June 7, 2021, the company and its officers are alleged to have misled investors by, among … Continue reading "SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-13T13:34:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC70970&sd=2022-09-13\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm\",\"datePublished\":\"2022-09-13T13:34:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\\\/\"},\"wordCount\":395,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC70970&sd=2022-09-13\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\\\/\",\"name\":\"SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC70970&sd=2022-09-13\",\"datePublished\":\"2022-09-13T13:34:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC70970&sd=2022-09-13\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC70970&sd=2022-09-13\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm - Market Newsdesk","og_description":"PR Newswire SAN FRANCISCO , Sept. 13, 2022 \/PRNewswire\/ — Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) relating to possible false and misleading statements to investors about its Alzheimer’s drug Aduhelm and an alleged illegal kickback scheme.\u00a0 Biogen and three of its executive officers are currently subject to a class action securities lawsuit in the U.S. District Court for the District of Massachusetts in which plaintiffs allege certain false and misleading statements concerning the commercial prospects for the company’s Alzheimer’s drug, Aduhelm. Specifically, following the FDA’s controversial approval of the drug on June 7, 2021, the company and its officers are alleged to have misled investors by, among … Continue reading \"SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-13T13:34:31+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC70970&sd=2022-09-13","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm","datePublished":"2022-09-13T13:34:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/"},"wordCount":395,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC70970&sd=2022-09-13","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/","name":"SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC70970&sd=2022-09-13","datePublished":"2022-09-13T13:34:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC70970&sd=2022-09-13","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC70970&sd=2022-09-13"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/684741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=684741"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/684741\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=684741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=684741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=684741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}